DOUGLAS RICHARD — SEC Form 4 filings
SEC reporting owner CIK 1021015. 12 Form 4 filings on record with FilingPulse; latest filed 2026-06-23.
Transaction summary — filings shown
Covers all 12 filings on record, filed 2024-06-06 to 2026-06-23. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 2 legs across 2 filings — 150,000 shares, $209,040 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 27.
- Largest priced transaction: purchase of 80,000 shares @ $1.39 ($111,040) in MAXCYTE, INC., filed 2025-08-13.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| MAXCYTE, INC. (MXCT) | Director | 4 | 1 leg · 80,000 sh · $111,040 | — | 6 |
| Aldeyra Therapeutics, Inc. (ALDX) | Director | 4 | 1 leg · 70,000 sh · $98,000 | — | 9 |
| NOVAVAX INC (NVAX) | Director | 4 | — | — | 12 |
Form 4 filings — DOUGLAS RICHARD
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-23 | 4 | NOVAVAX INC (NVAX) | Option exercise (M): 18,880 · Grant/award (A): 21,270 (derivative) @ $0 · Grant/award (A): 14,180 (derivative) @ $0 · Option exercise (M): 18,880 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | MAXCYTE, INC. (MXCT) | Grant/award (A): 30,421 @ $0 · Grant/award (A): 49,579 (derivative) @ $0 | EDGAR |
| 2026-06-11 | 4 | Aldeyra Therapeutics, Inc. (ALDX) | Grant/award (A): 70,000 (derivative) @ $0 · Grant/award (A): 19,909 (derivative) @ $0 · Grant/award (A): 2,323 (derivative) @ $0 | EDGAR |
| 2026-03-20 | 4 | Aldeyra Therapeutics, Inc. (ALDX) | Purchase (P): 70,000 @ $1.40 | EDGAR |
| 2025-08-13 | 4 | MAXCYTE, INC. (MXCT) | Purchase (P): 80,000 @ $1.39 | EDGAR |
| 2025-06-24 | 4 | NOVAVAX INC (NVAX) | Grant/award (A): 28,326 (derivative) @ $6.42 · Grant/award (A): 18,884 (derivative) @ $0 | EDGAR |
| 2025-06-23 | 4 | MAXCYTE, INC. (MXCT) | Grant/award (A): 29,210 @ $0 · Grant/award (A): 50,790 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | NOVAVAX INC (NVAX) | Option exercise (M): 10,420 @ $0 · Option exercise (M): 10,420 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | Aldeyra Therapeutics, Inc. (ALDX) | Grant/award (A): 62,728 (derivative) @ $0 · Grant/award (A): 14,476 (derivative) @ $0 · Grant/award (A): 1,689 (derivative) @ $0 | EDGAR |
| 2024-06-14 | 4 | NOVAVAX INC (NVAX) | Option exercise (M): 6,670 @ $0 · Option exercise (M): 6,670 (derivative) @ $0 · Grant/award (A): 15,630 (derivative) @ $15.86 · Grant/award (A): 10,420 (derivative) @ $0 | EDGAR |
| 2024-06-13 | 4 | MAXCYTE, INC. (MXCT) | Grant/award (A): 21,367 @ $0 · Grant/award (A): 40,701 (derivative) @ $0 | EDGAR |
| 2024-06-06 | 4 | Aldeyra Therapeutics, Inc. (ALDX) | Grant/award (A): 40,282 (derivative) @ $0 · Grant/award (A): 10,418 (derivative) @ $0 · Grant/award (A): 1,215 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1021015 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →